Paradigm has results from its Phase 2 hay fever trial pending in six weeks.
ACCESS THE FULL PRESENTATION HERE
M Pharma has in the year expanded its treatment portfolio, added significant revenue to the bottom line and received FDA pathway approval for its C-103
John Martin discussed regenerative medicine with investors.
"In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently